Physician profile
Edwin Yee
NPI 1851409270
$9,404.16
in general payments reported to CMS, 2019-2025
17 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $1,457 · 2021: $1,917 · 2022: $1,757 · 2023: $1,458 · 2024: $835 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,777 · Education: $29.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.86 |
| Education | $29.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $2,453.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $2,240.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $1,313.03 | 2021-2025 | |
| Novo Nordisk INC | $858.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $693.43 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $412.82 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.28 | 2019-2023 | Jardiance, Tradjenta |
| Lilly USA, LLC | $375.69 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $191.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $167.08 | 2022-2025 | |
| Esperion Therapeutics, INC. | $146.05 | 2020-2024 | Nexletol |
| Horizon Therapeutics Plc | $47.50 | 2021-2023 | Krystexxa |
| Abbott Laboratories | $46.72 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $27.44 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $22.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.62 | 2019 | |
| Merck Sharp & Dohme LLC | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.